(1-甲基环戊基)甲胺 | 100555-73-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (1-甲基环戊基)甲胺
• 英文名称: (1-methyl-cyclopentylmethyl)-amine
• 英文别名: (1-Methylcyclopentyl)methanamine
• CAS: 100555-73-5
• 化学式: C₇H₁₅N
• mdl: MFCD02690451
• 分子量: 113.203
• InChiKey: GCMLGSALHMDQFS-UHFFFAOYSA-N

物化性质

• 沸点：
  130.8±8.0 °C(Predicted)
• 密度：
  0.858±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921300090

反应信息

• 作为反应物：
  描述：

  (1-甲基环戊基)甲胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 (S)-1-[(1-Methyl-cyclopentylmethyl)-carbamoyl]-piperidine-2-carboxylic acid benzyl ester
  参考文献：
  名称：

  Structure-Based Design of Novel, Urea-Containing FKBP12 Inhibitors

  摘要：

  The structure-based design and subsequent chemical synthesis of novel, urea-containing FKBP12 inhibitors are described. These compounds are shown to disrupt the cis-trans peptidylprolyl isomerase activity of FKBP12 with inhibition constants (K-i,K-app) approaching 0.10 mu M. Analyses of several X-ray crystal structures of FKBP12-urea complexes demonstrate that the urea-containing inhibitors associate with FKBP12 in a manner that is similar to, but significantly different from, that observed for the natural product FK506.

  DOI：

  10.1021/jm950798a
• 作为产物：
  描述：

  1-methylcyclopentanecarbonitrile 生成 (1-甲基环戊基)甲胺
  参考文献：
  名称：

  DICKORE, K.;EUE, L.;SCHMIDT, R. -R.;SANTEL, H. -J.

  摘要：

  DOI：

文献信息

• Purinone Derivatives as Tyrosine Kinase Inhibitors
  申请人：Principia Biopharma Inc.

  公开号：US20140142099A1

  公开（公告）日：2014-05-22

  The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as autoimmune diseases, cancer and inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

  本公开提供了一些酪氨酸激酶抑制剂及其药用盐，特别是BLK、BMX、EGFR、HER2、HER4、ITK、TEC、BTK和TXK，因此适用于治疗通过抑制酪氨酸激酶可治疗的疾病，如自身免疫疾病、癌症和炎症性疾病。还提供了含有这些化合物和药用盐的药物组合物，以及制备这些化合物和药用盐的方法。
• N-heterocyclic inhibitors of TNF-alpha expression
  申请人：——

  公开号：US20020065270A1

  公开（公告）日：2002-05-30

  N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: 1 Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-&agr; expression utilizing compounds of the present invention are also disclosed.

  抑制 p38 激酶从而阻断细胞因子产生的 N-杂环化合物已被披露。在一种实施例中，本发明的化合物由式 I 表示。还披露了利用本发明化合物的生产方法、药物组合物以及治疗与不当 p38 激酶活性或 TNF-α 表达相关的疾病的方法。
• N- heterocyclic inhibitors of TNF-alpha expression
  申请人：——

  公开号：US20020137747A1

  公开（公告）日：2002-09-26

  N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: 1 Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-&agr; expression utilizing compounds of the present invention are also disclosed.

  揭示了通过抑制p38激酶阻断细胞因子产生的N-杂环化合物。在一种实施例中，本发明的化合物由式I表示。还揭示了利用本发明的化合物生产方法、制药组合物以及治疗与不当p38激酶活性或TNF-α表达相关的疾病的方法。
• N-heterocyclic inhibitors of TNF-α expression
  申请人：Moriarty Kevin Joseph

  公开号：US06906067B2

  公开（公告）日：2005-06-14

  N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula I: Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.

  本发明揭示了通过抑制p38激酶来阻断细胞因子产生的N-杂环化合物。在一个实施例中，本发明的化合物由式I表示。还公开了利用本发明的化合物治疗与不当p38激酶活性或TNF-α表达相关的疾病的方法、制备方法和药物组合物。
• [EN] N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION<br/>[FR] INHIBITEURS N-HETEROCYCLIQUES DE L'EXPRESSION DE TNF-ALPHA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2003002542A1

  公开（公告）日：2003-01-09

  N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula (I). Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-a expression utilizing compounds of the present invention are also disclosed.

  本发明揭示了一种通过抑制p38激酶来阻止细胞因子产生的N-杂环化合物。在一种实施例中，本发明的化合物由式(I)表示。本发明还揭示了利用本发明的化合物生产方法、制药组合物以及治疗与不适当的p38激酶活性或TNF-a表达相关的疾病的方法。